A phase I trial of cyclosporine for hospitalized patients with COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.06.10.21258714: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This investigator-initiated trial protocol was approved by the Institutional Review Board (IRB) at the University of Pennsylvania and was overseen by the Center for Cellular Immunotherapies (IND#149997, ClinicalTrials.gov identifier: NCT04412785).
Consent: Informed consent was obtained from each patient.Sex as a biological variable Also excluded were pregnant or lactating women and patients receiving investigational vaccines for SARS-CoV-2. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical analyses were performed using Prism 8 GraphPad (GraphPad Software). Prismsuggested: (PRISM, RRID:SCR_005375)SciScore for 10.1101/2021.06.10.21258714: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This investigator-initiated trial protocol was approved by the Institutional Review Board (IRB) at the University of Pennsylvania and was overseen by the Center for Cellular Immunotherapies (IND#149997, ClinicalTrials.gov identifier: NCT04412785).
Consent: Informed consent was obtained from each patient.Sex as a biological variable Also excluded were pregnant or lactating women and patients receiving investigational vaccines for SARS-CoV-2. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical analyses were performed using Prism 8 GraphPad (GraphPad Software). Prismsuggested: (PRISM, RRID:SCR_005375)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are several limitations to this study. Given the variable epidemiology of COVID-19 and the changing therapeutics during our study period, our enrollment was impacted and the number studied is small. The small numbers also affected our ability to estimate whether there was a significant clinical effect for our patients, independently of those related to corticosteroids and remdesivir. In summary, we show that CSA is a safe and potentially effective therapeutic intervention for patients with SARS-CoV-2 infection. Its anti-inflammatory properties, wide availability, safety and low cost make it a particularly attractive modality for use in resource-limited settings. A prospective randomized controlled trial testing the efficacy of cyclosporine for the treatment of COVID-19 pneumonia is registered in Spain [20]. Based on our results further large-scale trials are warranted to explore the safety and benefits of this intervention globally.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04412785 Active, not recruiting Cyclosporine in Patients With Moderate COVID-19 Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
